Pharma: Other News To Note
Wednesday, November 27, 2013
• Boehringer Ingelheim GmbH, of Ingelheim, Germany, said its marketing authorization application for faldaprevir, a second-generation oral protease inhibitor, was fully validated and granted accelerated assessment by the European Medicines Agency.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.